Impact of Hypoglossal Nerve Stimulation on Consumer Sleep Technology Metrics and Patient Symptoms - PubMed (original) (raw)

Randomized Controlled Trial

. 2024 Jul;134(7):3406-3411.

doi: 10.1002/lary.31398. Epub 2024 Mar 22.

Affiliations

Randomized Controlled Trial

Impact of Hypoglossal Nerve Stimulation on Consumer Sleep Technology Metrics and Patient Symptoms

Yi Cai et al. Laryngoscope. 2024 Jul.

Abstract

Objectives: Obstructive sleep apnea (OSA) is usually assessed at discrete and infrequent timepoints. Wearable consumer sleep technologies (CST) may allow for more granular and longitudinal assessments of OSA therapy responses and OSA-related symptoms.

Methods: In this case series, we enrolled hypoglossal nerve stimulator (HGNS) patients who had an effective treatment response for an 8-week study using a wearable CST. Participants started with "HGNS-on," were randomized to turn off HGNS therapy during either week 4 or 5 ("HGNS-off"), followed by a return to therapy, "HGNS-resume." Participants completed validated symptom questionnaires assessing sleepiness, insomnia symptoms, functional status, and overall sleep health (Satisfaction, Alertness, Timing, Efficiency, and Duration, SATED) each week. CST metrics and survey scores were compared between HGNS treatment phases. Associations between CST metrics and survey scores were assessed.

Results: Seven participants with a total of 304 nights of CST data showed no statistically significant changes in total sleep time (TST), wake time after sleep onset, or sleep efficiency (SE) across the study periods. During HGNS-off, survey scores indicated significantly worsened OSA-related symptom scores. Two participants had significantly higher heart rate variability (HRV) during HGNS-off (by 3.3 and 6.3 ms) when compared to HGNS active therapy periods. Amongst CST metrics, SATED scores correlated with TST (r = 0.434, p < 0.0001), HRV (r = -0.486, p < 0.0001), and SE (r = 0.320, = 0.0014). In addition, FOSQ-10 scores correlated with average HR during sleep (r = -0.489, p < 0.001).

Conclusion: A 1-week HGNS therapy withdrawal period impacted OSA-related sleep symptoms. Sleep-related metrics measured by a wearable CST correlated with symptom scores indicating potential value in the use of CSTs for longitudinal sleep-tracking in OSA patients.

Level of evidence: 4 Laryngoscope, 134:3406-3411, 2024.

Keywords: consumer sleep technology; hypoglossal nerve stimulator; obstructive sleep apnea; sleep quality; sleep symptoms; wearables.

© 2024 The American Laryngological, Rhinological and Otological Society, Inc.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep apnea. Int Forum Allergy Rhinol. 2023;13:1061‐1482. https://doi.org/10.1002/alr.23079.
    1. Cai Y, Tripuraneni P, Gulati A, et al. Patient‐defined goals for obstructive sleep apnea treatment. Otolaryngol Head Neck Surg. 2022;167:791‐798. https://doi.org/10.1177/01945998221075298.
    1. Gulati A, Stephens EM, Cai Y, Chang JL. Characterizing decisional conflict in patients presenting to sleep surgery clinic and an exploration of resource limitations. Laryngoscope. 2021;131(10):2384‐2390. https://doi.org/10.1002/lary.29695.
    1. de Zambotti M, Rosas L, Colrain IM, Baker FC. The sleep of the ring: comparison of the ŌURA sleep tracker against polysomnography. Behav Sleep Med. 2019;17(2):124‐136. https://doi.org/10.1080/15402002.2017.1300587.
    1. Kinnunen H. Sleep Lab validation of a wellness ring in detecting sleep patterns based on photoplethysmogram, actigraphy and body temperature. Accessed February 1, 2023. https://blog.ouraring.com/oura-validation-psg/.

Publication types

MeSH terms

LinkOut - more resources